Skip to contentpdufa.bio

4D-110

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

4D-110 is a 4D Molecular Therapeutics, Inc. program. Its next catalyst is a Readout in May 2027.

FDMT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: 4D Molecular Therapeutics, Inc. (FDMT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · May 2027FDMT

Specialist biotech funds holding FDMT, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management5,049,779$72.3 millionfiled November 16, 2026
BVF Inc.2,879,289$41.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is 4D-110's next FDA decision or readout?

The next tracked catalyst for 4D-110 is a Readout in May 2027.

What happened at 4D-110's most recent FDA decision?

No FDA decision for 4D-110 is in our archive yet.

Who makes 4D-110?

4D Molecular Therapeutics, Inc. (FDMT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.